These findings also have important implications for AD treatment as demonstrated by recent studies by Snow et al. (2018) and as shown in other related studies (Djordjevic et al., 2017; Adlimoghaddam et al., 2019) that suggest targeting NF-κB signaling in the mitochondria may have therapeutic value. The gene discussed is NFKB1; the disease is Alzheimer disease.